melphalan


Also found in: Dictionary, Thesaurus, Acronyms, Wikipedia.

melphalan

 [mel´fah-lan]
a cytotoxic alkylating agent derived from nitrogen mustard, used as an antineoplastic agent, primarily for treatment of multiple myeloma; administered orally or intravenously.

melphalan

/mel·pha·lan/ (mel´fah-lan) a cytotoxic alkylating agent derived from mechlorethamine, used as an antineoplastic.

melphalan

[mel′fəlan]
an antineoplastic alkylating agent.
indications It is prescribed in the treatment of malignant neoplastic diseases, including palliative treatment of multiple myeloma and nonresectable ovarian carcinoma.
contraindications Pregnancy, recent exposure to antineoplastic medication or to radiation, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse effects are bone marrow depression, nausea, and vomiting.

melphalan

An alkylating nitrogen mustard used to treat ovarian cancer, myeloma, and occasionally melanoma.

Adverse effects
Nausea, vomiting, oral ulcers, myelosuppression, mutagenesis, allergic reactions.

melphalan

Alkeran® Oncology An oral alkylating anticancer nitrogen mustard agent used to treat  ovarian CA and myeloproliferative disease Adverse effects Myelosuppression, mutagenesis

melphalan

A drug used in the treatment of POLYCYTHAEMIA VERA, chronic LEUKAEMIA and MYELOMATOSIS. A brand name is Alkeran.

melphalan

(mel´fəlan´),
n brand name: Alkeran;
drug class: antineoplastic;
action: responsible for cross-linking DNA strands, which leads to cell death;
uses: palliative treatment of multiple myeloma and nonresectable epithelial carcinoma of the ovary.

melphalan

a cytotoxic nitrogen mustard alkylating agent used as an antineoplastic.
References in periodicals archive ?
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced data from the Phase II study with its Captisol-enabled([R]), propylene glycol-free (PG-free) melphalan.
Captisol-enabled melphalan demonstrated a marginally greater melphalan systemic exposure (~110%) than was realized from Alkeran.
The data presented today help build a strong case that this new Captisol-enabled formulation of Melphalan could be a significant improvement over the standard of care for patients going through myeloablation," said Dr.
In the Phase 3 VELCADE + melphalan and prednisone study, the safety profile of VELCADE in combination with melphalan/prednisone is consistent with the known safety profiles of both VELCADE and melphalan/prednisone.
In December 2008, CyDex received orphan-drug designation from the FDA for melphalan "as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation," which would grant the company seven years of exclusive marketing rights upon approval.
United States-based Spectrum Pharmaceuticals has submitted a new drug application for Captisol-Enabled Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) to the United States Food and Drug Administration.
IND acceptance for Captisol-enabled melphalan is an important milestone for CyDex as we work to develop a portfolio of new drugs for the hospital acute care market," said Theron E.
It is currently marketed in China by BeiGene under an exclusive license from Celgene (CELG) In a large randomized, three-arm, open-label Phase 3 trial (CC-5013-MM-020) conducted to compare the efficacy and safety of Revlimid and low dose dexamethasone to that of melphalan, prednisone and thalidomide in patients with newly diagnosed multiple myeloma who were not eligible for transplant, continuous Revlimid plus dexamethasone significantly improved median progression-free survival compared to the MPT arm.
Biotechnology company Genmab A/S (CPH:GEN) announced on Friday that the US Food and Drug Administration (FDA) has granted the company Priority Review to the supplemental Biologics License Application (sBLA) for the use of daratumumab (DARZALEX) in combination with bortezomib, melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Janssen Research & Development, LLC today announced data from the Phase 3 ALCYONE study, showing that DARZALEX (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).
Trials comparing efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in transplant-ineligible or elderly patients with multiple myeloma (MM) have provided conflicting evidence.
36 treated 95 eyes of 78 patients with intra-arterial melphalan, topotecan, carboplatin or methotrexate as a primary or secondary treatment modality; they reported globe conservation at rates of 81.